XNAS
NAGE
Market cap206mUSD
Oct 08, Last price
2.66USD
1D
-2.21%
1Q
-21.53%
Jan 2017
-19.64%
IPO
-70.44%
Name
Chromadex Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ChromaDex Corporation is a bioscience enterprise committed to advancing healthy aging. The company's operations are segmented into three primary areas: Consumer Products, Ingredients, and Analytical Reference Standards and Services. Its research efforts largely concentrate on nicotinamide adenine dinucleotide (NAD+). Under its Consumer Products division, ChromaDex provides finished dietary supplements, which incorporate its proprietary ingredients, directly to consumers and through distributors. A flagship offering is TRU NIAGEN, a supplement featuring NIAGEN, the company's proprietary nicotinamide riboside (an NAD+ precursor) as its active component. The Ingredients segment is responsible for the development and commercialization of specialized ingredient technologies. It supplies these unique raw materials, including NIAGEN, to other manufacturers for use in their consumer products. Another significant ingredient is IMMULINA, composed of Braun-type lipoproteins and spirulina extracts, which is designed to support immune system function. Additionally, ChromaDex offers analytical reference standards and services. These products are vital for performing quality control checks on raw materials and finished goods within industries such as dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceuticals. TRU NIAGEN products reach consumers via multiple channels, including ChromaDex's dedicated e-commerce site, TRUNIAGEN.com, as well as Amazon and other online marketplaces. Distribution also extends to specialty retailers and directly to healthcare practitioners within the United States. ChromaDex Corporation's main office is located in Los Angeles, California.
Key people
Senior Vice President - Finance, Secretary · since 2017
Lisa Bratkovich
Chief Marketing Officer · since 2018
Matthew A. Roberts
Senior Vice President - Innovation, Chief Scientific Officer · since 2018
Mark Friedman
General Counsel, Corporate Secretary · since 2018
Brianna Gerber
Senior Director of FP&A, IR Contact Officer · since 2018
Frank L. Jaksch
Executive Chairman of the Board · since 2018
Stephen Allen
Independent Chairman of the Board · since 2015
Robert N. Fried
President, Chief Executive Officer, Chief Operating Officer, Chief Strategy Officer, Director · since 2018
Independent Director · since 2015
Stephen A. Block
Independent Director · since 2011
Lead Independent Director · since 2018
Tony Lau
Independent Director · since 2017
Independent Director · since 2017
Wendy Yu
Independent Director · since 2017
IPO date
Jun 25, 2007
Employees
113
Domiciled in
US
Incorporated in
US
Legal address
c/o Business Filings Incorporated, 108 West, 13th Street
Wilmington, DE 19801
US
Wilmington, DE 19801
US
Headquarters
10005 Muirlands Boulevard, Suite G,
Irvine, CA 92618
US
Irvine, CA 92618
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||